
AMCP strongly supports the passage of the MVP Act. Medicaid beneficiaries are among America's most vulnerable patients. Value-based payment arrangements are a critical tool for promoting patient access to high-quality, affordable care.
We are writing to express our support for the Biosimilars Competition Act of 2018 (H.R. 6478). The undersigned stakeholders share your commitment to promoting a biosimilars market that will help reduce prescription drug costs for patients, payers, and taxpayers. We commend you for introducing this important legislation and look forward to working with you to enact it into law.
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.